]>
IRCT20160811029306N1 IRCT 2018-10-06 National Institute for Medical Research Development Vitamin c in Diabetes Effects of ascorbic acid on AGEs, AOPP ,FRAP, hsp70,hsCRP, ox- LDL ,leptinand HOMA in patients with type 2diabetes 2018-10-23 anticipated 70 Complete https://irct.ir/trial/33209 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: This is a randomized double blind clinical trial study, Blinding description: This is a double blind study.Both participants and investigator are blind. N/A Type 2 diabetes. Intervention 1: Intervention group: Oral Vitamin c supplement. Intervention 2: Control group: placebo. No - There is not a plan to make this available Justification or reason for not sharing IPD is Given the confidentiality of the information of the patients participating in this study, I do not intend to publish the participant's data file.
public Manouchehr Nakhjavani
No 21,Vali- asr hospital, Keshavarz Bolvd, Tehran,Iran
Tehran Iran (Islamic Republic of) 14197-33147 +98 21 6691 1294 nakhjavanim@tums.ac.ir Tehran University of Medical Sciences scientific Manouchehr Nakhjavani
No 21,Vali- asr hospital, Keshavarz Bolvd, Tehran,Iran
Tehran Iran (Islamic Republic of) 14197-33147 +98 21 6691 1294 nakhjavanim@tums.ac.ir Tehran University of Medical Sciences Iran (Islamic Republic of) type2 diabetes older than 30 30 years 65 years Both type1 diabetes pregnancy renal failure history ofheart failure liver failure malignancy smoking acute inflammation infection hypersensitivity to vitamin C current vitamins use E08 Diabetes mellitus due to underlying condition Prevention Prevention Intervention group: Oral Vitamin c supplement Control group: placebo Advancedglycation end products(AGEs). Timepoint: Blood samples will be taken before treatment and after 2 month of treatment. Method of measurement: AGEs will be measured by the spectrophotometric method in endocrine laboratory of vali-asr hospital. AOPP. Timepoint: Blood samples will be taken before treatment and after 2 month of treatment. Method of measurement: AOPP concentrations will be measured by spectrophotometric methods. FRAP. Timepoint: Blood samples will be taken before treatment and after 2 month of treatment. Method of measurement: FRAP will be assessed by spectrophotometric method. Ox LDL. Timepoint: Blood samples will be taken before treatment and after 2 month of treatment. Method of measurement: OX LDL will be measured using commercially available sandwich enzymelinked immunosorbent assay. HSP70. Timepoint: Blood samples will be taken before treatment and after 2 month of treatment. Method of measurement: HSP70 will be measured using a quantitative sandwich ELISA immunoassay. Hs-CRP. Timepoint: Blood samples will be taken before treatment and after 2 month of treatment. Method of measurement: Hs-CRP will be assessed by a two-site enzyme-linked immunosorbent assay. Leptin. Timepoint: Blood samples will be taken before treatment and after 2 month of treatment. Method of measurement: Leptin leptin concentration will be measured by an ELISA assay. Insulin. Timepoint: Blood samples will be taken before treatment and after 2 month of treatment. Method of measurement: Fasting insulin was measured using radioimmunoassay techniques. National Institute for Medical Research Development Approved 2018-07-01 Ethics committee of National Institute for Medical Research Development No 21, Besat Ave, West Fatemi Blvd,Tehran Tehran Tehran Iran (Islamic Republic of)